Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Accounts Payables: 2015-2024

Historic Accounts Payables for Wave Life Sciences (WVE) over the last 10 years, with Dec 2024 value amounting to $16.3 million.

  • Wave Life Sciences' Accounts Payables rose 13.37% to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year increase of 13.37%. This contributed to the annual value of $16.3 million for FY2024, which is 26.66% up from last year.
  • Wave Life Sciences' Accounts Payables amounted to $16.3 million in FY2024, which was up 26.66% from $12.8 million recorded in FY2023.
  • Wave Life Sciences' 5-year Accounts Payables high stood at $16.9 million for FY2022, and its period low was $7.3 million during FY2021.
  • Its 3-year average for Accounts Payables is $15.3 million, with a median of $16.3 million in 2024.
  • In the last 5 years, Wave Life Sciences' Accounts Payables plummeted by 47.22% in 2021 and then spiked by 132.32% in 2022.
  • Over the past 5 years, Wave Life Sciences' Accounts Payables (Yearly) stood at $13.8 million in 2020, then slumped by 47.22% to $7.3 million in 2021, then spiked by 132.32% to $16.9 million in 2022, then declined by 24.10% to $12.8 million in 2023, then rose by 26.66% to $16.3 million in 2024.